These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 23862585)

  • 1. Comparison of bevacizumab and cabergoline in the treatment of ovarian hyperstimulation syndrome in a rat model.
    Engin-Ustun Y; Yılmaz S; Timur H; Ustun Y; Moraloglu O; Deveer R; Yılmaz N
    Gynecol Endocrinol; 2013 Sep; 29(9):851-4. PubMed ID: 23862585
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of montelukast and cabergoline for prevention of ovarian hyperstimulation syndrome: in an experimental rat model.
    Akman L; Sahin G; Erbas O; Aktug H; Akdogan A; Goker EN; Taskiran D; Tavmergen E
    Gynecol Endocrinol; 2015 May; 31(5):369-73. PubMed ID: 25599748
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevention of ovarian hyperstimulation syndrome in a rat model: efficacy comparison between cabergoline and meloxicam.
    Saylan A; Arioz DT; Koken T; Dilek H; Saylan F; Yilmazer M
    Acta Obstet Gynecol Scand; 2010 May; 89(5):692-9. PubMed ID: 20423279
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A potential novel strategy, inhibition of vasopressin-induced VEGF secretion by relcovaptan, for decreasing the incidence of ovarian hyperstimulation syndrome in the hyperstimulated rat model.
    Cenksoy C; Cenksoy PO; Erdem O; Sancak B; Gursoy R
    Eur J Obstet Gynecol Reprod Biol; 2014 Mar; 174():86-90. PubMed ID: 24405730
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison between resveratrol and cabergoline in preventing ovarian hyperstimulation syndrome in a rat model.
    Kasap E; Turan GA; Eskicioğlu F; Cengiz H; Gur EB; Sivrikoz ON; Genc M; Yılmaz O
    Gynecol Endocrinol; 2016 Aug; 32(8):634-640. PubMed ID: 26939766
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Montelukast is effective in preventing of ovarian hyperstimulation syndrome; an experimental study.
    Eskicioğlu F; Turan GA; Sivrikoz ON; Cengiz H; Zafer A; Akan Z; Sahin N; Yilmaz O; Yeşil H; Vatansever S
    Ginekol Pol; 2015 Aug; 86(8):566-73. PubMed ID: 26492704
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low-dose dopamine agonist administration blocks vascular endothelial growth factor (VEGF)-mediated vascular hyperpermeability without altering VEGF receptor 2-dependent luteal angiogenesis in a rat ovarian hyperstimulation model.
    Gomez R; Gonzalez-Izquierdo M; Zimmermann RC; Novella-Maestre E; Alonso-Muriel I; Sanchez-Criado J; Remohi J; Simon C; Pellicer A
    Endocrinology; 2006 Nov; 147(11):5400-11. PubMed ID: 16901966
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the effects of letrozole and cabergoline on vascular permeability, ovarian diameter, ovarian tissue VEGF levels, and blood PEDF levels, in a rat model of ovarian hyperstimulation syndrome.
    Şahin N; Apaydın N; Töz E; Sivrikoz ON; Genç M; Turan GA; Cengiz H; Eskicioğlu F
    Arch Gynecol Obstet; 2016 May; 293(5):1101-6. PubMed ID: 26690356
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dopamine receptor 2 activation inhibits ovarian vascular endothelial growth factor secretion in an ovarian hyperstimulation syndrome (OHSS) animal model: implications for treatment of OHSS with dopamine receptor 2 agonists.
    Ferrero H; García-Pascual CM; Gaytán M; Morales C; Simón C; Gaytán F; Pellicer A; Gómez R
    Fertil Steril; 2014 Nov; 102(5):1468-1476.e1. PubMed ID: 25217874
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oxytocin and cabergoline alleviate ovarian hyperstimulation syndrome (OHSS) by suppressing vascular endothelial growth factor (VEGF) in an experimental model.
    Hortu I; Karadadas E; Ozceltik G; Tavmergen E; Tavmergen Goker EN; Yigitturk G; Erbas O
    Arch Gynecol Obstet; 2021 Apr; 303(4):1099-1108. PubMed ID: 33140116
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ovarian hyperstimulation syndrome inhibition by targeting VEGF, COX-2 and calcium pathways: a preclinical randomized study.
    Kitsou C; Kosmas I; Lazaros L; Hatzi E; Euaggelou A; Mynbaev O; Tournaye H; Prapas N; Prapas I; Zikopoulos K; Galani V; Georgiou I
    Gynecol Endocrinol; 2014 Aug; 30(8):587-92. PubMed ID: 24819316
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevention of ovarian hyperstimulation syndrome in a rat model: comparison of the efficacy of tocilizumab with that of ranibizumab, cabergoline, and a gonadotropin-releasing hormone antagonist.
    Taskin MI; Topcu O; Yay A; Erken G; Balcioğlu E; Adali E; Hismiogulları AA
    Gynecol Endocrinol; 2015; 31(12):949-54. PubMed ID: 26369707
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Administration of a gonadotropin-releasing hormone agonist affects corpus luteum vascular stability and development and induces luteal apoptosis in a rat model of ovarian hyperstimulation syndrome.
    Scotti L; Irusta G; Abramovich D; Tesone M; Parborell F
    Mol Cell Endocrinol; 2011 Mar; 335(2):116-25. PubMed ID: 21238536
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of cyclooxygenase-2 (COX-2) by meloxicam decreases the incidence of ovarian hyperstimulation syndrome in a rat model.
    Quintana R; Kopcow L; Marconi G; Young E; Yovanovich C; Paz DA
    Fertil Steril; 2008 Oct; 90(4 Suppl):1511-6. PubMed ID: 18166186
    [TBL] [Abstract][Full Text] [Related]  

  • 15. What is the impact of short- and long-term supplementation of either cabergoline or clarithromycin on resolving rat ovarian hyperstimulation syndrome (OHSS) model?
    Atilgan R; Pala Ş; Yavuzkır Ş; Başpınar M; Yılmaz M; Ilhan N
    J Obstet Gynaecol; 2019 Jul; 39(5):687-694. PubMed ID: 30892121
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Everolimus, an mTOR pathway inhibitor, is highly successful on ovarian hyperstimulation syndrome by reducing ovarian weight and progesterone levels: a preclinical experimental randomized controlled study.
    Kosmas IP; Kitsou C; Lazaros L; Markoula S; Peschos D; Mynbaev O; Tournaye H; Prapas N; Prapas I; Zikopoulos A; Galani V; Georgiou I
    Gynecol Endocrinol; 2015; 31(9):702-7. PubMed ID: 26172931
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vivo intrabursal administration of bioactive lipid sphingosine-1-phosphate enhances vascular integrity in a rat model of ovarian hyperstimulation syndrome.
    Di Pietro M; Pascuali N; Scotti L; Irusta G; Bas D; May M; Tesone M; Abramovich D; Parborell F
    Mol Hum Reprod; 2017 Jun; 23(6):417-427. PubMed ID: 28379469
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aflibercept suppresses ovarian hyperstimulation syndrome: an experimental study in rats.
    Ateş Ç; Dilbaz B; Ergani SY; Atabay F
    Rev Assoc Med Bras (1992); 2023; 69(11):e20230789. PubMed ID: 37909622
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Does cabergoline administration affect endometrial VEGFR-2 expression in a rat model of ovarian hyperstimulation syndrome?
    Yilmaz N; Gulsen Coban P; Yilmaz S; Inal HA; Timur H; Haltas H
    Gynecol Endocrinol; 2023 Dec; 39(1):2217295. PubMed ID: 37247633
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of varying doses of tamoxifen on ovarian histopathology, serum VEGF, and endothelin 1 levels in ovarian hyperstimulation syndrome: an experimental study.
    Pala Ş; Atilgan R; Ozkan ZS; Kavak SB; Ilhan N; Akpolat N; Sapmaz E
    Drug Des Devel Ther; 2015; 9():1761-6. PubMed ID: 25848212
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.